On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).
Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.
For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.
Learn more about Otezla® (apremilast) prescribing, efficacy and safety, patient savings, and more from an Otezla Sales Representative. Your sales rep can also provide Otezla Starter Kits
Main Contact Information
Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1789
+1 805-447-1000
Medical Information
Medical questions or adverse event reports can be directed to Amgen Inc. Medical Information at:
Phone
800-77-AMGEN (800-772-6436)
Email
medinfo@amgen.com
Otezla® (apremilast) is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.
Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
Contraindications
Warnings and Precautions
Adverse Reactions
Use in Specific Populations
Please click here for Full Prescribing Information.
Otezla® (apremilast) is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Otezla is indicated for the treatment of adult patients with active psoriatic arthritis.
Otezla is indicated for the treatment of adult patients with oral ulcers associated with Behçet’s Disease.
Contraindications
Warnings and Precautions
Adverse Reactions
Use in Specific Populations
Please click here for Full Prescribing Information.